Guangliang Qiang

Prof. Dr. Guangliang Qiang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ZTZhoujunyi Tian
Zhoujunyi Tian
CLChaoyang Liang
Chaoyang Liang
ZZZhenrong Zhang
Zhenrong Zhang
HWHuanshun Wen
Huanshun Wen
HFHongxiang Feng
Hongxiang Feng
GQGuangliang Qiang
Guangliang Qiang
Background: Neuron-specific enolase (NSE) has become a widely used and easily attainable laboratory assay of small cell lung cancer (SCLC). However, the prognostic value of NSE for SCLC patients remains controversial. The aim of the study was to evaluate the correlation between elevated serum NSE before therapy and survival of SCLC patients. Methods: We performed a systematic review and meta-analysis. A systematic literature search was conducted in PubMed, Embase, and the Cochrane Central Register from the inception dates to December 2019. Eligible articles were included according to inclusion and exclusion criteria; then, data extraction and quality assessment were performed. The primary outcome was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Results: We identified 18 studies comprising 2981 patients. Pooled results revealed that elevated NSE was associated with worse OS (HR = 1.78, 95% CI 1.55–2.06, p < 0.001) and PFS (HR = 1.50, 95% CI 1.16–1.93, p = 0.002). In subgroup analysis, elevated NSE did not predict worse OS in patients who received only chemotherapy (HR 1.22, 95% CI 0.96–1.55, p = 0.10) or part of whom received surgical resection before chemotherapy and radiotherapy (HR = 2.16, 95% CI 0.82–5.69, p = 0.12). Conclusion: Elevated serum NSE before any therapy of SCLC patients may be a negative prognostic factor for OS and PFS. The prognostic value of NSE for OS was particularly observed in patients treated by standard management.

7 January 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
QLQicai Liu
Qicai Liu
ZHZhichao Hu
Zhichao Hu
THTao Huang
Tao Huang
YNYupeng Niu
Yupeng Niu
XZXinche Zhang
Xinche Zhang
GQGuangliang Qiang
Guangliang Qiang
Multidisciplinary tumor boards (MDTs) are central to cancer care but remain constrained by scarce experts and variable decision quality. EvoMDT employs a self-evolution loop that updates prompts, consensus weights, and retrieval scope based on expert feedback and outcome signals, improving robustness without sacrificing traceability. This matters clinically because MDT workloads and evidence shift over time, requiring adaptive yet auditable decision support. Agents perform domain-specific inference over lesion-level clinical data with structured knowledge retrieval; a consensus protocol resolves conflicts and generates traceable, evidence-linked recommendations. Evaluation spanned six public oncology QA benchmarks and four real-world datasets (breast, liver, lung, lymphoma), followed by single-blind physician assessment. Quantitative metrics (ROUGE, BERTScore) and automated safety checks assessed factuality and guideline concordance, while clinicians rated clinical appropriateness and usability. EvoMDT outperformed frontier Large Language Models (LLMs) baselines (e.g., Llama-3-70B, Claude-3, Med-PaLM 2), improving guideline concordance and semantic alignment with expert plans (BERTScore 0.62–0.68) and reducing safety violations. In physician review, EvoMDT achieved decision quality comparable to human MDTs while shortening response time by 30–40%. These results position EvoMDT as an interpretable, evidence-traceable framework that operationalizes AI reasoning for multidisciplinary oncology practice and offers a scalable foundation for trustworthy, lesion-level precision cancer care.

1 December 2015 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
DLDeruo Liu
Deruo Liu
GQGuangliang Qiang
Guangliang Qiang
CLChaoyang Liang
Chaoyang Liang
FXFei Xiao
Fei Xiao
QYQiduo Yu
Qiduo Yu
YGYongqing Guo
Yongqing Guo
Purpose: This study aimed to determine whether the severity of chronic obstructive pulmonary disease (COPD) affects recurrence-free survival in non-small-cell lung cancer (NSCLC) patients after surgical resection. Patients and methods: A retrospective study was performed on 421 consecutive patients who had undergone lobectomy for NSCLC from January 2008 to June 2011. Classification of COPD severity was based on guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Characteristics among the three subgroups were compared and recurrence-free survivals were analyzed. Results: A total of 172 patients were diagnosed with COPD (124 as GOLD-1, 46 as GOLD-2, and two as GOLD-3). The frequencies of recurrence were significantly higher in patients with higher COPD grades (P<0.001). Recurrence-free survival at 5 years was 78.1%, 70.4%, and 46.4% in non-COPD, mild COPD, and moderate/severe COPD groups, respectively (P<0.001). By univariate analysis, the age, sex, smoking history, COPD severity, tumor size, histology, and pathological stage were associated with recurrence-free survival. Multivariate analysis showed that older age, male, moderate/severe COPD, and advanced stage were independent risk factors associated with recurrence-free survival. Conclusion: NSCLC patients with COPD are at high risk for postoperative recurrence, and moderate/severe COPD is an independent unfavorable prognostic factor.

4 July 2025 in Journal of Advanced Research
Verified
Journal Article
Open access
LZLan Zhen
Lan Zhen
MMMin Min
Min Min
XMXinglin Mo
Xinglin Mo
GZGuilin Zhao
Guilin Zhao
HLHuilong Li
Huilong Li
RZRuzhou Zhao
Ruzhou Zhao
Macrophages play crucial regulatory roles within the tumor immune microenvironment (TIME) and significantly influence tumor progression. GOLM1 has been identified as being closely associated with a variety of cancers. Nevertheless, the role of GOLM1 in macrophages on tumor progression remains unknown. This study aims to investigate the mechanism by which the GOLM1-ACLY axis in macrophages regulates tumor progression. The orthotopic hepatocellular carcinoma (HCC) inoculationand subcutaneous tumor implantation were used to establish mouse tumor models. The expression levels of the indicated proteins were assessed by immunohistochemistry and immunoblotting. Coimmunoprecipitation (Co-IP), mass spectrometry (MS), and immunofluorescence were employed to determine the interactions between proteins. Bulk RNA sequencing was used to explore the mRNA profiles in bone marrow-derived monocytes (BMDMs). Moreover, qPCR was used to quantify the mRNA levels. CUT&Tag sequence and qPCR assays were performed to assess the DNA sequences bound by H3K27ac. We identified that GOLM1 was observed to be markedly upregulated in macrophages from both liver/lung cancer patients and mouse tumor models. Macrophage deletion of GOLM1 suppressed tumor proliferation and provoked metabolic reprogramming in tumor cells. IP-MS analysis identified the Adenosine triphosphate citrate lyase (ACLY) protein as an interacting partner of GOLM1. Mechanistically, GOLM1 could bind to ACLY and impede the phosphorylation of ACLY by protein kinase A (PKA). The knockout of GOLM1 significantly increased the P-ACLY level in the nucleus of macrophage. Specifically, elevated P-ACLY significantly promoted monoacetylation at lysine 27 of histone H3 (H3K27ac). Combined analysis of CUT&Tag-seq and RNA-seq date further revealed a notable decrease of H3K27ac levels in the EFEMP1 gene, which promoted tumor proliferation via EGFR-MAPK/AKT signaling Genetic or pharmacological intervention via Acly-targeted siRNA or the ACLY inhibitor known as bempedoic acid (BA) abolished the tumor-suppressive effect induced by macrophage-specific GOLM1 deletion. Our findings reveal a novel mechanism involving the GOLM1-ACLY axis within macrophages that regulates tumor progression, which suggest a potential strategy for tumor intervention.

3 September 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
SLShengyi Li
Shengyi Li
YHYue Hu
Yue Hu
LYLexin Yang
Lexin Yang
BLBaohua Lv
Baohua Lv
XKXue Kong
Xue Kong
GQGuangliang Qiang
Guangliang Qiang
Background: Pneumonia and tuberculosis are prevalent pulmonary diseases globally, each demanding specific care measures. However, distinguishing between these two conditions imposes challenges due to the high skill requirements for doctors, the impact of imaging positions and respiratory intensity of patients, and the associated high healthcare costs, emphasizing the imperative need for intelligent and efficient diagnostic methods.Method: This study aims to develop a highly accurate automatic diagnosis and classification method for various lung diseases (Normal, Pneumonia, and Tuberculosis). We propose a hybrid model, which is based on the InceptionV3 architecture, enhanced by introducing Deepwise Separable Convolution after the Inception modules and incorporating the Squeeze-and-Excitation mechanism. This architecture successfully enables the model to extract richer features without significantly increasing the parameter count and computational workload, thereby markedly improving the performance in predicting and classifying lung diseases. To objectively assess the proposed model, external testing and five-fold cross-validation were conducted. Additionally, widely used baseline models in the scholarly community were constructed for comparison.Result: In the external testing phase, the our model achieved an average accuracy (ACC) of 90.48% and an F1-score (F1) of 91.44%, which is an approximate 4% improvement over the best-performing baseline model, ResNet. In the five-fold cross-validation, our model’s average ACC and F1 reached 88.27% ± 2.76% and 89.29% ± 2.69%, respectively, demonstrating exceptional predictive performance and stability. The results indicate that our model holds promise for deployment in clinical settings to assist in the diagnosis of lung diseases, potentially reducing misdiagnosis rates and patient losses.Conclusion: Utilizing deep learning for automatic assistance in the diagnosis of pneumonia and tuberculosis holds clinical significance by enhancing diagnostic accuracy, reducing healthcare costs, enabling rapid screening and large-scale detection, and facilitating personalized treatment approaches, thereby contributing to widespread accessibility and improved healthcare services in the future.

24 September 2021 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
JZJin Zhang
Jin Zhang
FXFei Xiao
Fei Xiao
GQGuangliang Qiang
Guangliang Qiang
ZZZhenrong Zhang
Zhenrong Zhang
QMQianli Ma
Qianli Ma
CLChaoyang Liang
Chaoyang Liang
Background. The competitive endogenous RNA (ceRNA) mechanism has been discovered recently and regulating cancer-related gene expressions. The ceRNA network participates in multiple processes, such as cell proliferation and metastasis, and potentially drives the progression of cancer. In this study, we focus on the ceRNA networks of esophageal squamous cell carcinoma and discovered a novel biomarker panel for cancer prognosis. Methods. RNA expression data of esophageal carcinoma from the TCGA database were achieved and constructed ceRNA network in esophageal carcinoma using R packages. Results. Four miRNAs were discovered as the core of the ceRNA model, including miR-93, miR-191, miR-99b, and miR-3615. Moreover, we constructed a ceRNA network in esophageal carcinoma, which included 4 miRNAs and 6 lncRNAs. After ceRNA network modeling, we investigated six lncRNAs which could be taken together as a panel for prognosis prediction of esophageal cancer, including LINC02575, LINC01087, LINC01816, AL136162.1, AC012073.1, and AC117402.1. Finally, we tested the predictive power of the panel in all TCGA samples. Conclusions. Our study discovered a new biomarker panel which may have potential values in the prediction of prognosis of esophageal carcinoma.